Analytical Data
-
Gene name
Kininogen1
- Application
-
Alternative Names
Kininogen1；
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01042-2
-
Expression Region
19-380aa
-
AA Sequence
MASMTGGQQMGRGHHHHHHGNLYFQGGEFQESQSEEIDCNDKDLFKAVDA ALKKYNSQNQSNNQFVLYRITEATKTVGSDTFYSFKYEIKEGDCPVQSGK TWQDCEYKDAAKAATGECTATVGKRSSTKFSVATQTCQITPAEGPVVTAQ YDCLGCVHPISTQSPDLEPILRHGIQYFNNNTQHSSLFMLNEVKRAQRQV VAGLNFRMTYSIVQTNCSKENFLFLTPDCKSLWNGDTGECTDNAYIDIQL RIASFSQNCDIYPGKDFVQPPTKICVGCPRDIPTNSPELEETLTHTITKL NAENNATFYFKIDNVKKARVQVVAGKKYFIDFVARETTCSKESNEELTES CETKKLGQSLDCNAEVYVVPWEKKIYPTVNCQPLGMISLMK
-
Molecular Weight
48 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Kininogen1 is a key component of the kallikrein-kinin system, which plays a vital role in various physiological processes, including blood pressure regulation, inflammation, and pain modulation. The study of Kininogen1 has gained significant attention due to its potential implications in cardiovascular diseases and other inflammatory disorders. As a precursor to bradykinin, Kininogen1 can influence vascular permeability and smooth muscle contraction, making it an important target for therapeutic interventions. Recent advancements in recombinant protein technology have enabled the production of Kininogen1 in heterologous systems, facilitating a deeper understanding of its structure-function relationship and biological activities. Research on recombinant Kininogen1 not only provides insights into its interaction with kallikrein and bradykinin receptors but also offers opportunities for developing novel biomarker assays and therapeutic agents. With growing evidence linking dysregulation of the kallikrein-kinin system to various health conditions, the exploration of Kininogen1 as a biomolecular agent holds promise for innovative treatment strategies aimed at mitigating cardiovascular risk factors and enhancing anti-inflammatory responses.
